Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BioVie Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BIVI
Nasdaq
2836
bioviepharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BioVie Inc.
BioVie says bezisterim shows distinct responses in two Long COVID patient groups
- Nov 16th, 2026 7:57 am
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
- Nov 16th, 2026 6:00 am
BioVie to present additional Parkinson’s drug data at international conference
- Nov 10th, 2026 7:32 am
BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases
- Nov 10th, 2026 6:00 am
BioVie identifies two Long COVID patient groups with distinct responses to bezisterim
- Nov 9th, 2026 7:28 am
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
- Nov 9th, 2026 6:00 am
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
- Nov 7th, 2026 10:05 am
BioVie to raise $4.74 million in registered direct offering
- Nov 4th, 2026 7:01 am
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- Nov 4th, 2026 6:00 am
BioVie to present new Long COVID biomarker data at Nice conference
- Nov 2nd, 2026 7:50 am
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
- Nov 2nd, 2026 7:00 am
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
- Oct 31st, 2026 10:00 am
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
- Oct 26th, 2026 6:00 am
MARKETS LIVE: Wall Street rebounds as Anthropic IPO filing revives AI trade
- Oct 26th, 2026 4:48 am
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
- Oct 24th, 2026 8:30 am
BioVie reports positive Phase 2 Parkinson’s data for bezisterim
- Oct 20th, 2026 7:53 am
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
- Oct 20th, 2026 6:00 am
BioVie showcases Long COVID and Parkinson’s data at ANA2026, with findings in Annals of Neurology
- Oct 19th, 2026 12:04 pm
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
- Oct 19th, 2026 6:00 am
MARKETS LIVE: Nasdaq leads Wall Street higher as tech shares recover
- Oct 19th, 2026 4:59 am
Scroll